Recall of Rabewell-20 medication due to substandard quality.

The Hanoi Department of Health has announced the recall of Rabewell-20 enteric-coated tablets due to substandard quality.

The Hanoi Department of Health has announced the recall of Rabewell-20 enteric-coated tablets due to substandard quality.

Specifically, the enteric-coated tablets Rabewell-20 (Rabeprazole Sodium), Registration Number: VN-13640-11, Batch Number: ME23A40, Manufacturing Date: 18/01/2023, Expiry Date: 17/01/2026, manufactured by The Madras Pharmaceuticals (India), imported by A My Pharmaceutical Co., Ltd., and distributed by My Anh Trading and Service Joint Stock Company, failed to meet the quality requirements for quantitative analysis.

Illustrative image.

The Hanoi Department of Health has requested My Anh Trading and Service Joint Stock Company to thoroughly recall Rabewell-20 enteric-coated tablets (Rabeprazole Sodium), Registration Number: VN-13640-11, Batch Number: ME23A40, Manufacturing Date: 18/01/2023, Expiry Date: 17/1/2026; and to submit a recall report and recall documentation as required.

In addition, public and private healthcare facilities, pharmaceutical businesses, and drug retailers in the area are urged to promptly review and recall the aforementioned batch of substandard drugs.

The Health Departments of districts, counties, and towns shall notify healthcare facilities within their jurisdiction; and conduct inspections and monitoring of the facilities' implementation of the recall (if any).

Previously, the Hanoi Department of Health issued a notice suspending the circulation and recalling nationwide four skin-whitening and anti-pigmentation cosmetic products that did not meet quality standards.

Specifically, the products subject to recall include: Whitening and sunscreen cream SPF 30, brand SH Today Hai Duong Cosmetics, 10g box, manufactured on March 4, 2024, with an expiration date of 3 years from the date of manufacture, produced by Hai Duong Cosmetics Production and Trading Co., Ltd. ( Ho Chi Minh City).

This product is being recalled because the test sample failed to meet quality standards, containing Methylparaben and Propylparaben, which are not included in the formula as stated in the cosmetic product declaration certificate.

The second product is the 3-in-1 Dark Spot Cream, brand SH Today Hai Duong Cosmetics, 15g box, manufactured on November 22, 2023, with an expiration date of 3 years from the date of manufacture, also produced by Hai Duong Cosmetics Manufacturing and Trading Co., Ltd. in Ho Chi Minh City.

This product is being recalled because the test sample failed to meet quality standards and contains Propylparaben, which is not included in the formula for which the cosmetic product declaration certificate was issued.

The Bảo Xinh brand whitening and anti-spot cream, 12g box, manufactured on November 1, 2024, with a shelf life of 3 years from the date of manufacture, produced by Bảo Xinh Cosmetics Joint Stock Company (Hau Giang), was also recalled because the test sample failed to meet quality standards, containing Phenoxyethanol, a substance not included in the formula for which the cosmetic product declaration certificate was issued.

Finally, the product "Spot-Reducing Moisturizing Sunscreen Cream," brand Sứ Tiên, 8g box, manufactured on February 20, 2024, with an expiration date of February 20, 2027, produced by Anh Đào Cosmetics Manufacturing Co., Ltd. (Kiên Giang), was also recalled because the test sample failed to meet quality standards due to the presence of salicylic acid, which is not included in the formula for which the cosmetic product declaration certificate was issued.

The Hanoi Department of Health has requested that all businesses and users of cosmetics in the area urgently review and immediately cease the sale and use of the aforementioned product batches.

Businesses are required to return the products to the supplier and proceed with a complete recall of all substandard products. The Health Department will supervise and inspect the recall process by businesses and users of cosmetics in the area.

Regarding drug quality, according to the World Health Organization (WHO), approximately 11% of medicines in developing countries are counterfeit and may be responsible for the deaths of tens of thousands of children each year from diseases such as malaria or pneumonia.

Through 100 studies involving 48,000 types of medications, experts concluded that, among counterfeit drugs, those for treating malaria and infections accounted for nearly 65%.

In Vietnam, the recent surge in counterfeit and substandard drugs has caused considerable concern and anxiety among many people. Statistics from the National Institute for Drug Testing show that in 2021, the nationwide testing system inspected the quality of over 500 pharmaceutical active ingredients and 300 medicinal herbs; 338 samples were found to be substandard.

Specifically, 118 out of 28,659 domestic drug samples failed to meet quality standards (0.41%), and this rate was 26 out of 3,042 imported drugs (0.86%). In addition, testing revealed 20 suspected counterfeit drug samples, an increase of 11 samples compared to the same period last year.

It is known that the National Strategy for the Development of Vietnam's Pharmaceutical Industry for the period up to 2030 and with a vision to 2045 sets the goal that by 2030, 100% of medicines will be proactively and promptly supplied to meet the needs of disease prevention and treatment; ensuring drug security, meeting the requirements of national defense and security, disease prevention and control, overcoming the consequences of natural disasters, public health incidents, and other urgent needs for medicines.

Domestically produced medicines are striving to meet approximately 80% of domestic demand and 70% of market value. Efforts will continue to be made to achieve the goal of producing 20% ​​of the raw materials needed for domestic drug production. Domestically produced vaccines will meet 100% of the needs for the expanded immunization program and 30% of the needs for private immunization services.

Vietnam strives to become a high-value pharmaceutical manufacturing hub in the region. This includes receiving technology transfer and coordinating the processing and production of at least 100 original branded drugs, vaccines, and biological products, including biosimilars, as well as some drugs that Vietnam does not yet produce.

Source: https://baodautu.vn/thu-hoi-thuoc-rabewell-20-khong-dat-tieu-chuan-chat-luong-d247650.html